| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0264-410X(95)00127-M |
| P698 | PubMed publication ID | 8701596 |
| P2093 | author name string | Kasel JA | |
| Couch RB | |||
| Kilbourne ED | |||
| Johansson BE | |||
| Cate TR | |||
| Keitel WA | |||
| Grajower B | |||
| Pokorny BA | |||
| Quarles JH | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1799-1803 | |
| P577 | publication date | 1995-12-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans | |
| P478 | volume | 13 |
| Q33782762 | A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects |
| Q50686159 | A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. |
| Q77392508 | A sensitive and specific ELISA immunocapture assay for rapid quantitation of influenza A/H3N2 neuraminidase protein |
| Q30372164 | Advances in the development of influenza virus vaccines. |
| Q45730050 | Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase. |
| Q36075789 | Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. |
| Q37976539 | Correlates of vaccine protection from influenza and its complications |
| Q30372274 | Emerging influenza viruses and the prospect of a universal influenza virus vaccine. |
| Q81866414 | Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography |
| Q42225065 | Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus |
| Q92376471 | Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase |
| Q45438480 | Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system |
| Q73520468 | Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents |
| Q33820732 | In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen |
| Q33889558 | Influenza and respiratory syncytial virus. Update on infection, management, and prevention |
| Q30385397 | Influenza immunology evaluation and correlates of protection: a focus on vaccines. |
| Q30399269 | Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir |
| Q41676828 | Influenza vaccines. A reappraisal of their use. |
| Q38045918 | Influenza vaccines: T-cell responses deserve more attention |
| Q38160083 | Influenza vaccines: from whole virus preparations to recombinant protein technology |
| Q34717840 | Influenza vaccines: present and future |
| Q30249879 | Influenza virus neuraminidase (NA): a target for antivirals and vaccines |
| Q35629114 | Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines |
| Q30386823 | Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies |
| Q22305647 | Making better influenza virus vaccines? |
| Q41053445 | Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge |
| Q30420126 | N-linked glycosylation in the hemagglutinin of influenza A viruses |
| Q52609074 | NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? |
| Q36408162 | Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets |
| Q39810755 | Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. |
| Q35826733 | Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future |
| Q57202936 | Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics |
| Q30376724 | Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity. |
| Q38580454 | Prospects for broadly protective influenza vaccines |
| Q49093623 | Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase |
| Q45750536 | Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin |
| Q84557620 | Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences |
| Q40334782 | Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry |
| Q36462309 | Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines |
| Q34697810 | Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects |
| Q30411052 | Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry |
| Q30360024 | Stability of neuraminidase in inactivated influenza vaccines. |
| Q28297557 | Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans |
| Q35118696 | Streptococcus iniae SF1: complete genome sequence, proteomic profile, and immunoprotective antigens |
| Q36836699 | The threat of avian influenza A (H5N1). Part IV: Development of vaccines. |
| Q47551663 | Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines |
| Q73032435 | What are the prospects for a universal influenza vaccine? |
Search more.